An Integrated Approach to Smoking Cessation in Severe Mental Illness (SMI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00690131 |
Recruitment Status
:
Completed
First Posted
: June 4, 2008
Last Update Posted
: March 30, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Smoking Cessation | Behavioral: BTSCS | Not Applicable |
Smoking is the leading cause of preventable death in the United States, contributing to increased rates of lung cancer and heart disease, and adding complications to other health problems. Over 70% of people with serious mental illnesses (SMI) smoke, a rate that is double that of the general population and remains high despite decreases in overall smoking rates. Smoking contributes to elevated morbidity and mortality in SMI, has other life-threatening consequences, and increases health care costs in SMI. While treating smoking is a critical step in improving the health of people with SMI, there are features of SMI that make treatment difficult (low motivation to quit, symptoms, barriers to attendance, cognitive deficits, poor social functioning). Stop-smoking groups have had limited success in achieving smoking cessation (SC), likely because they have not been tailored for people with SMI. SC for SMI must address the deficits and barriers to change found in this population, and must be integrated with mental health services.
This study will involve the design and small-scale clinical trial of a behavioral treatment program for SC in people with SMI called Behavioral Treatment for Smoking Cessation in Serious and Persistent Mental Illness (BTSCS) in two psychosocial rehabilitation programs (PRPs) in Baltimore.
We will first provide basic education for PRP staff regarding smoking cessation in SMI to promote smoking cessation as a goal of mental health treatment. We will then pilot test BTSCS with components that include: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention. Our primary aims are: (1) Develop intervention materials and examine feasibility, acceptability, and safety; (2) Measure the effects of the intervention at post-treatment and 3-month follow-up on rates of smoking cessation, number of quit attempts, rates of smoking reduction and intention/motivation to quit smoking.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 219 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Integrated Approach to Smoking Cessation in SMI |
Actual Study Start Date : | August 2009 |
Actual Primary Completion Date : | May 2015 |
Actual Study Completion Date : | May 2015 |
Arm | Intervention/treatment |
---|---|
Experimental: 1 |
Behavioral: BTSCS
BTSCS includes: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention.
|
No Intervention: 2 |
- Smoking abstinence: percentage of participants reporting abstinence reported in the 7-day interval at post-treatment and follow-up [ Time Frame: 7-day interval at post-treatment and follow-up ]
- Smoking abstinence: average percentage of biweekly sessions with negative expired carbon monoxide (CO) levels (< 8 ppm) [ Time Frame: from baseline to post treatment ]
- Number of smoking quit attempts: self-reported number of quit attempts (for at least 24 hours) at post treatment and 3 month follow-up [ Time Frame: time from baseline to post treatment and baseline to 3 month follow-up ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Severe and Persistent Mental Illness (schizophrenia, schizoaffective disorder or other severe mental disorder including bipolar disorder, major depression, or severe anxiety disorder).
- Age between 18 and 75 years.
- Current smokers who smoke at least 10 cigarettes per day.
- Must have been seen by a psychiatrist at least every 3 months for the last 6 months.
Exclusion Criteria:
- Meet criteria for current alcohol/substance dependence (other than nicotine).
- Documented mental retardation, history of severe head injury with LOC, severe and untreated seizure disorder

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00690131
United States, Maryland | |
University of Maryland Baltimore | |
Baltimore, Maryland, United States, 21201 | |
Harbor City Unlimited | |
Baltimore, Maryland, United States | |
New Ventures, Sheppard Pratt | |
Timonium, Maryland, United States |
Principal Investigator: | Melanie E Bennett, Ph.D. | University of Maryland |
Responsible Party: | University of Maryland |
ClinicalTrials.gov Identifier: | NCT00690131 History of Changes |
Other Study ID Numbers: |
HP-00043121 1R34MH080814-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | June 4, 2008 Key Record Dates |
Last Update Posted: | March 30, 2017 |
Last Verified: | March 2017 |
Keywords provided by University of Maryland:
Smoking cessation, severe mental illness, behavioral treatment |